Tarveda
is a biopharmaceutical company that discovers and develops miniaturized drug conjugates for the treatment of solid tumor malignancies... Read moreTarveda
is a biopharmaceutical company that discovers and develops miniaturized drug conjugates for the treatment of solid tumor malignancies... Read more
2011
PrivateSubsidiary of Organovo Holdings, Inc.
News
Nov 01, 2021
Business Wire
Press Release: Tarveda : Tarveda Therapeutics Announces Data from Phase 2 Trial of PEN-221 to Be Presented at NANETS 2021 Multidisciplinary NET Virtual Symposium
Oct 13, 2021
MarketScreener
Tarveda: Tarveda Therapeutics to Present at Solebury Trout/BMO Private Company Showcase
Sep 16, 2021
MarketScreener
Tarveda: Tarveda Therapeutics and SciClone Pharmaceuticals Expand Partnership by Entering into a License Agreement for HSP90-PI3K Miniature Drug Conjugates in Greater China
Jun 04, 2021
Business Wire
Press Release: Tarveda : Tarveda Therapeutics Presents Promising Phase 2 Data of PEN-221 in Gastrointestinal Mid-gut Neuroendocrine Tumors
May 20, 2021
Business Wire
Press Release: Tarveda : Tarveda Therapeutics to Present Data from Phase 2 Study of PEN-221 at 2021 ASCO Annual Meeting
Oct 01, 2020
Boston Citybizlist
Tarveda: Tarveda Therapeutics Appoints Brian Roberts as CEO
Aug 04, 2020
Business Wire
Press Release: Tarveda : Tarveda Therapeutics Publishes Preclinical Study Evaluating HSP90 Binding Miniature Drug Conjugate with Pan-PI3K Payload in Solid Tumors
Jul 30, 2020
Drug Genius
Tarveda: Tarveda Therapeutics to Present at Upcoming Conferences
May 13, 2020
Acrofan
Tarveda: Tarveda Therapeutics Reports Complete Data from Phase 1 Portion of Phase 1/2a Study of PEN-866 to be Presented at the ASCO20 Virtual Scientific Progra
Apr 27, 2020
Acrofan
Tarveda: Tarveda Therapeutics Presents Pharmacokinetic and Tumor Biopsy Data from First in Human Study of PEN-866 at the 2020 AACR Virtual Annual Meeting
Tarveda Competitors
1
2
3
4
5
6
7
8
9
10